Comments
Drug firm Strides Pharma Science on Thursday posted 68.8 per cent decline in consolidated profit at ₹92.33 crore for the quarter ended December 31, 2019.
The company had posted consolidated profit of ₹296.43 crore in the year-ago period, Strides Pharma Science said in a regulatory filing.
However, the consolidated income of the company increased to ₹744.66 crore in the October-December period, as against ₹579.54 crore a year ago.
“Our contrarian strategies continue to play out for the regulated markets, which are now delivering growth with industry-leading post research and development (R&D) EBITDA margins,” Strides Pharma Science founder Arun Kumar said.
Earnings before interest, tax, depreciation and amortization (EBITDA) is a measure of a company’s operating performance.
Kumar further noted that “while we are clearly tracking ahead of our plans for the regulated markets, the emerging markets are still a few quarters behind from demonstrating an improved performance anticipated by the strategic actions undertaken by the company to improve its quality of business“.
Shares of Strides Pharma Science were trading at ₹480.70 a piece on BSE, up 7.56 per cent from the previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.